CGMP/QSR/Medical Devices/Adulterated: FDA Warning Letter to Nipro Renal Solutions USA, Corporation, 2026-07-24
Letter issued · posted to fda.gov .
Subject as published: CGMP/QSR/Medical Devices/Adulterated
TL;DR
Here's the summary: FDA Center for Devices and Radiological Health issued a warning letter (CMS #732874, July 24, 2026) to Nipro Renal Solutions USA, Corporation, Lewisberry PA, regarding hemodialysis dialysate concentrate solutions manufactured at the facility. The FDA inspection (February 2–March 27, 2026) found the devices adulterated under 21 CFR Part 820 due to failure to control nonconforming product: the firm released multiple lots of MedicaLyte Bicarbonate Powder and Citric Complete Dry Citric Acid Concentrate with out-of-specification endotoxin results (May 6, 2025; December 18, 2025; May 22, 2025) and failed to document investigations for thirteen additional endotoxin failures from January 2025–February 2026, despite having procedures requiring such documentation. The FDA rejected the firm's response that retesting of retained samples justified releasing the original lots without customer notification, stating endotoxin levels higher than specification pose a health risk, and requested documentation of planned actions for the released lots and completion of corrective action plans 26004 and 26005.
Argus analysis
# FDA Warning Letter Analysis: Nipro Renal Solutions USA, Corporation
**Company and Findings**
Nipro Renal Solutions USA, Corporation, a manufacturer of dry and liquid hemodialysis dialysate concentrate solutions located in Lewisberry, Pennsylvania, received a Warning Letter from the FDA's Center for Devices and Radiological Health on July 24, 2026, following a facility inspection conducted from February 2 through March 27, 2026. The FDA determined that the company's hemodialysis products are adulterated because manufacturing methods and facility controls fail to comply with current good manufacturing practice requirements.
**Regulatory Citations and Implications**
The violations primarily cite 21 CFR Part 820, the Quality Management System Regulation, and align with ISO 13485:2016 standards. Key citations include failures in nonconforming product control (21 CFR § 820.90), corrective and preventive action procedures (21 CFR § 820.100), and design control documentation (21 CFR § 820.30). These sections establish foundational requirements for medical device quality systems. The company released multiple hemodialysis product lots with out-of-specification endotoxin levels, failed to document investigations for thirteen documented endotoxin failures, and demonstrated ineffective corrective actions with recurring nonconformances. The FDA noted that products exceeding endotoxin specifications posed potential health risks.
**Response Timeline and Industry Monitoring**
Nipro submitted responses on April 17, May 29, and July 14, 2026, with corrective actions remaining incomplete as of the Warning Letter issuance. The company promised revisions to quality procedures and CAPA tracking system implementation with an August 7, 2026 target date. Peer compliance officers should monitor for follow-up correspondence, product recalls, or import detention actions. Particular attention should focus on whether the company addresses endotoxin testing documentation, nonconforming product disposition, and the effectiveness verification of promised corrective actions within stated timeframes.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Nipro Renal Solutions USA, Corporation MARCS-CMS 732874 — July 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices UDI Recipient: Recipient Name Tsuyoshi Yamazaki Recipient Title President Nipro Renal Solutions USA, Corporation 509 Fishing Creek Road Lewisberry , PA 17339 United States (b)(6), (b)(7)(C) Issuing Office: Center for Devices and Radiological Health United States Secondary Issuing Offices United States WARNING LETTER CMS # 732874 July 16, 2026 Dear Mr. Yamazaki: During an inspection of your firm located in Lewisberry, PA from February 2, 2026 through March 27, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures dry and liquid hemodialysis dialysate concentrate solutions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Quality Management System Regulation Violations This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Rachael Nelsen, Vice President of Quality Affairs & Regulatory Affairs, dated April 17, 2026 and May 29, 2026, and from Vikram Chandra, Senior Vice President of Quality Affairs & Regulatory Affairs, dated July 14, 2026 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following: 1. Failure to ensure that product which does not conform to product requirements is identified and controlled to prevent its unintended use or delivery; and failure to document a procedure defining the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product, as required by ISO 13485:2016, Clause 8.3.1. Specifically, a. Your firm released and distributed finished hemodialysis products with out-of-specification (OOS) endotoxin results on multiple occasions. Specifically, your firm released the following lots of products despite your Laboratory Report Forms (DMR 5404) incorrectly indicated that endotoxin LAL testing had 'Passed,' and the Finished Product Packet (SOP QSM012; Eff…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Nipro Renal Solutions USA, Corporation had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Nipro Renal Solutions USA, Corporation as of 2026-08-18. Argus ingests new FDA enforcement records daily.
- What FDA violations was Nipro Renal Solutions USA, Corporation cited for?
- The FDA Warning Letter to Nipro Renal Solutions USA, Corporation (issuing office: Center for Devices and Radiological Health) cites: CGMP/QSR/Medical Devices/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Nipro Renal Solutions USA, Corporation?
- FDA issued the letter (MARCS-CMS 732874) on 2026-07-24 and posted it publicly on fda.gov on 2026-08-18.
- Is the FDA warning letter to Nipro Renal Solutions USA, Corporation publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nipro-renal-solutions-usa-corporation-732874-07242026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/QSR/Medical Devices/Adulterated: FDA Warning Letter to Nipro Renal Solutions USA, Corporation, 2026-07-24. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-nipro-renal-solutions-usa-corporation-2026-07-24-cgmp
"CGMP/QSR/Medical Devices/Adulterated: FDA Warning Letter to Nipro Renal Solutions USA, Corporation, 2026-07-24." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-nipro-renal-solutions-usa-corporation-2026-07-24-cgmp.
Argus HQ Research. "CGMP/QSR/Medical Devices/Adulterated: FDA Warning Letter to Nipro Renal Solutions USA, Corporation, 2026-07-24." Digital Empire Holdings LLC. Accessed August 19, 2026. https://argushq.ai/fda/warning-letter/fda-wl-nipro-renal-solutions-usa-corporation-2026-07-24-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_nipro_renal_solutions_usa_corporation_2026_07_24_cgmp_2026,
title = {CGMP/QSR/Medical Devices/Adulterated: FDA Warning Letter to Nipro Renal Solutions USA, Corporation, 2026-07-24},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-nipro-renal-solutions-usa-corporation-2026-07-24-cgmp},
note = {Accessed: August 19, 2026}
}